VRDN - Company ID 0001590750
Viridian Therapeutics, Inc.DE (VRDN) reported revenue of $70.85M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $70.85M | +23359.9% |
| FY 2024 | $302.00K | -3.8% |
| FY 2023 | $314.00K | -82.3% |
| FY 2022 | $1.77M | -40.2% |
| FY 2021 | $2.96M | +182.2% |
| FY 2020 | $1.05M | -76.5% |
| FY 2019 | $4.46M | -46.8% |
| FY 2018 | $8.39M | +109.5% |
| FY 2017 |
Viridian Therapeutics, Inc.DE (VRDN) reported revenue of $70.85M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2013 and fiscal 2025, Viridian Therapeutics, Inc.DE's revenue grew from $5.49M to $70.85M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.00M |
| +15.1% |
| FY 2016 | $3.48M | -39.1% |
| FY 2015 | $5.71M | -12.0% |
| FY 2014 | $6.48M | +18.1% |
| FY 2013 | $5.49M | - |